FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002114555> ?p ?o ?g. }

• W2002114555 endingPage "1196" @default.
• W2002114555 startingPage "1190" @default.
• W2002114555 abstract "In hypertrophic cardiomyopathy, the plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) correlate with functional capacity. However, their prognostic relevance remains unresolved. We followed up 183 stable outpatients with hypertrophic cardiomyopathy (age 50 ± 17 years, 64% men) for 3.9 ± 2.8 years after NT-proBNP measurement. The primary end point included cardiovascular death, heart transplantation, resuscitated cardiac arrest, and appropriate implantable cardioverter-defibrillator intervention. The secondary end point (SE) included heart failure-related death or hospitalization, progression to end-stage disease, and stroke. The median NT-proBNP level was 615 pg/ml (intertertile range 310 to 1,025). The incidence of the primary end point in the lower, middle, and upper tertiles was 0%, 1.3%, and 2.1% annually, respectively (overall p = 0.01). On multivariate analysis, the only independent predictors of the primary end point were NT-proBNP (hazard ratio for log-transformed values 5.8, 95% confidence interval 1.07 to 31.6; p = 0.04) and a restrictive left ventricular filling pattern (hazard ratio 5.19, 95% confidence interval 1.3 to 21.9; p = 0.02). The NT-proBNP cutoff value of 810 pg/ml had the best sensitivity for the primary end point (88%), but the specificity was low (61%). The incidence of the SE in the lower, middle, and upper NT-proBNP tertiles was 4.6%, 12.0%, and 11.2% annually, respectively (overall p = 0.001). An NT-proBNP level of <310 pg/ml was associated with a 75% reduction in the rate of SE compared with a level of ≥310 pg/ml (hazard ratio 0.25, 95% confidence interval 0.11 to 0.57; p = 0.001), independent of age, left ventricular outflow tract obstruction, or atrial fibrillation. In conclusion, in stable outpatients with hypertrophic cardiomyopathy, plasma NT-proBNP proved a powerful independent predictor of death and heart failure-related events. Although the positive predictive accuracy of an elevated NT-proBNP level was modest, low values reflected true clinical stability, suggesting the possibility of avoiding or postponing aggressive treatment options. In hypertrophic cardiomyopathy, the plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) correlate with functional capacity. However, their prognostic relevance remains unresolved. We followed up 183 stable outpatients with hypertrophic cardiomyopathy (age 50 ± 17 years, 64% men) for 3.9 ± 2.8 years after NT-proBNP measurement. The primary end point included cardiovascular death, heart transplantation, resuscitated cardiac arrest, and appropriate implantable cardioverter-defibrillator intervention. The secondary end point (SE) included heart failure-related death or hospitalization, progression to end-stage disease, and stroke. The median NT-proBNP level was 615 pg/ml (intertertile range 310 to 1,025). The incidence of the primary end point in the lower, middle, and upper tertiles was 0%, 1.3%, and 2.1% annually, respectively (overall p = 0.01). On multivariate analysis, the only independent predictors of the primary end point were NT-proBNP (hazard ratio for log-transformed values 5.8, 95% confidence interval 1.07 to 31.6; p = 0.04) and a restrictive left ventricular filling pattern (hazard ratio 5.19, 95% confidence interval 1.3 to 21.9; p = 0.02). The NT-proBNP cutoff value of 810 pg/ml had the best sensitivity for the primary end point (88%), but the specificity was low (61%). The incidence of the SE in the lower, middle, and upper NT-proBNP tertiles was 4.6%, 12.0%, and 11.2% annually, respectively (overall p = 0.001). An NT-proBNP level of <310 pg/ml was associated with a 75% reduction in the rate of SE compared with a level of ≥310 pg/ml (hazard ratio 0.25, 95% confidence interval 0.11 to 0.57; p = 0.001), independent of age, left ventricular outflow tract obstruction, or atrial fibrillation. In conclusion, in stable outpatients with hypertrophic cardiomyopathy, plasma NT-proBNP proved a powerful independent predictor of death and heart failure-related events. Although the positive predictive accuracy of an elevated NT-proBNP level was modest, low values reflected true clinical stability, suggesting the possibility of avoiding or postponing aggressive treatment options." @default.
• W2002114555 created "2016-06-24" @default.
• W2002114555 creator A5021505148 @default.
• W2002114555 creator A5028573057 @default.
• W2002114555 creator A5029153489 @default.
• W2002114555 creator A5033335493 @default.
• W2002114555 creator A5046643702 @default.
• W2002114555 creator A5060169707 @default.
• W2002114555 creator A5065763158 @default.
• W2002114555 creator A5067480096 @default.
• W2002114555 creator A5073773875 @default.
• W2002114555 creator A5081838991 @default.
• W2002114555 creator A5090207956 @default.
• W2002114555 creator A5090298902 @default.
• W2002114555 date "2013-10-01" @default.
• W2002114555 modified "2023-09-27" @default.
• W2002114555 title "Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide in Outpatients With Hypertrophic Cardiomyopathy" @default.
• W2002114555 cites W109657961 @default.
• W2002114555 cites W14674810 @default.
• W2002114555 cites W1977652818 @default.
• W2002114555 cites W1979534494 @default.
• W2002114555 cites W1982166104 @default.
• W2002114555 cites W1985934040 @default.
• W2002114555 cites W1986119723 @default.
• W2002114555 cites W1986122868 @default.
• W2002114555 cites W1989546228 @default.
• W2002114555 cites W1990763042 @default.
• W2002114555 cites W1992729026 @default.
• W2002114555 cites W2024102294 @default.
• W2002114555 cites W2041999536 @default.
• W2002114555 cites W2048293509 @default.
• W2002114555 cites W2070320179 @default.
• W2002114555 cites W2081848148 @default.
• W2002114555 cites W2102114313 @default.
• W2002114555 cites W2109560166 @default.
• W2002114555 cites W2113927128 @default.
• W2002114555 cites W2114663889 @default.
• W2002114555 cites W2118891131 @default.
• W2002114555 cites W2128908281 @default.
• W2002114555 cites W2136718447 @default.
• W2002114555 cites W2145651104 @default.
• W2002114555 cites W2168846504 @default.
• W2002114555 cites W2911339676 @default.
• W2002114555 cites W3186521396 @default.
• W2002114555 cites W4211100568 @default.
• W2002114555 cites W4249572792 @default.
• W2002114555 doi "https://doi.org/10.1016/j.amjcard.2013.06.018" @default.
• W2002114555 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23871673" @default.
• W2002114555 hasPublicationYear "2013" @default.
• W2002114555 type Work @default.
• W2002114555 sameAs 2002114555 @default.
• W2002114555 citedByCount "32" @default.
• W2002114555 countsByYear W20021145552014 @default.
• W2002114555 countsByYear W20021145552015 @default.
• W2002114555 countsByYear W20021145552016 @default.
• W2002114555 countsByYear W20021145552017 @default.
• W2002114555 countsByYear W20021145552018 @default.
• W2002114555 countsByYear W20021145552019 @default.
• W2002114555 countsByYear W20021145552020 @default.
• W2002114555 countsByYear W20021145552021 @default.
• W2002114555 countsByYear W20021145552022 @default.
• W2002114555 countsByYear W20021145552023 @default.
• W2002114555 crossrefType "journal-article" @default.
• W2002114555 hasAuthorship W2002114555A5021505148 @default.
• W2002114555 hasAuthorship W2002114555A5028573057 @default.
• W2002114555 hasAuthorship W2002114555A5029153489 @default.
• W2002114555 hasAuthorship W2002114555A5033335493 @default.
• W2002114555 hasAuthorship W2002114555A5046643702 @default.
• W2002114555 hasAuthorship W2002114555A5060169707 @default.
• W2002114555 hasAuthorship W2002114555A5065763158 @default.
• W2002114555 hasAuthorship W2002114555A5067480096 @default.
• W2002114555 hasAuthorship W2002114555A5073773875 @default.
• W2002114555 hasAuthorship W2002114555A5081838991 @default.
• W2002114555 hasAuthorship W2002114555A5090207956 @default.
• W2002114555 hasAuthorship W2002114555A5090298902 @default.
• W2002114555 hasConcept C120665830 @default.
• W2002114555 hasConcept C121332964 @default.
• W2002114555 hasConcept C126322002 @default.
• W2002114555 hasConcept C164705383 @default.
• W2002114555 hasConcept C168563851 @default.
• W2002114555 hasConcept C203092338 @default.
• W2002114555 hasConcept C207103383 @default.
• W2002114555 hasConcept C2775846464 @default.
• W2002114555 hasConcept C2775915353 @default.
• W2002114555 hasConcept C2777093960 @default.
• W2002114555 hasConcept C2778198053 @default.
• W2002114555 hasConcept C2778849806 @default.
• W2002114555 hasConcept C2780185194 @default.
• W2002114555 hasConcept C2909878339 @default.
• W2002114555 hasConcept C44249647 @default.
• W2002114555 hasConcept C61511704 @default.
• W2002114555 hasConcept C71924100 @default.
• W2002114555 hasConceptScore W2002114555C120665830 @default.
• W2002114555 hasConceptScore W2002114555C121332964 @default.
• W2002114555 hasConceptScore W2002114555C126322002 @default.
• W2002114555 hasConceptScore W2002114555C164705383 @default.
• W2002114555 hasConceptScore W2002114555C168563851 @default.
• W2002114555 hasConceptScore W2002114555C203092338 @default.

• next